Business Context and Reporting Period
This Form 8-K is filed by Nemus Bioscience, Inc. (referred to as Skye Bioscience, Inc. in the request metadata) for the reporting period ending January 9, 2017. The filing reports the consummation of a private placement financing involving the sale of Series D Convertible Preferred Stock to accredited investors.
Key Financial Metrics
- Total Financing Proceeds: $1,200,000 in aggregate gross proceeds from the sale of 1,200 Preferred Shares.
- Initial Closing (Jan 3, 2017): 500 shares sold for $500,000.
- Additional Closing (Jan 9, 2017): 700 shares sold for $700,000.
- Price Per Share: $1,000 per Series D Convertible Preferred Share.
- Placement Agent Compensation: Roth Capital Partners LLC received a warrant to purchase 480,000 shares of common stock at $0.25 per share.
- Debt and Liquidity: The filing text does not provide specific values for total debt, cash flow, or liquidity ratios.
Material Changes
The primary material change is the successful completion of a $1.2 million equity financing, which was previously announced on December 29, 2016. The company executed the financing in two tranches, raising the full intended amount of the initial tranche and a portion of the total authorized offering (up to 1,500 shares were authorized, 1,200 were sold in these closings).
Outlook, Risks, and Unusual Items
- Registration Rights: The company agreed to file a registration statement for the resale of underlying common stock within 30 days of the initial closing. If not effective within specified periods, the company must pay investors 2.0% of the aggregate purchase price monthly until effectiveness.
- Lock-Up Agreements: Officers and directors agreed to a 90-day lock-up on common stock sales, extending until the earlier of the effectiveness of a resale registration or eligibility under Rule 144.
- Preferred Stock Terms: The Series D stock includes anti-dilution protection, a "most favored nation" provision allowing exchange for future securities on equal terms, and a conversion price of $0.25 per share.
- Conversion Limitations: Conversion is limited to prevent any holder from acquiring beneficial ownership of more than 4.99% of outstanding common stock (increasable to 9.99% in certain circumstances).
Investor Verification Checklist
- Verify the total number of Series D shares sold versus the 1,500 authorized in the Certificate of Designation.
- Confirm the status of the registration statement for the resale of underlying common stock to assess potential 2.0% monthly penalty payments.
- Review the full text of the Lock-Up Agreements (Exhibit 10.1) for specific restrictions on insider trading.
- Assess the dilution impact of the 480,000 warrants issued to the placement agent.
- Check subsequent filings for the effectiveness of the resale registration statement.